We focus on the development and innovation of humanized models. Our R&D team developed the first highly immunodeficient controllable liver injury mouse model URG® in China in 2010, and the following year, we reached new heights by successfully developing the first humanized liver chimeric mouse Hu-URG® in China. As of 2023, after continuous optimization, the chimerism rate of Hu-URG® can reach 90%, and we have also launched new products B6-Fah and Hu-NPG-Fah. Weitongda is not only committed to the study of infectious liver disease models but also addresses the significant needs of MASH disease models. We have also been continuously launching new products such as Alms1 KO, KPA, HBV-MASH-HCC, etc., through gene editing technology.